Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Activase
(United States) [Available] ,Cathflo Activase
(United States) [Available]Synonyms :
Activase
Class :
Thrombolytics
Brand Name :
Activase
(United States) [Available] ,Cathflo Activase
(United States) [Available]Synonyms :
Activase
Class :
Thrombolytics
Dosage Forms & Strengths
Powder for injection
2mg(Cathflo activase)
50mg,100mg(Activase)
Do not exceed 100mg
Accelerated infusion(1-1/2 hr)-
≤67kg:
1 to 2 mins- 15mg IVP bolus
>30 mins-0.75mg/kg IV infusion
>60 mins-0.5mg/kg IV
≥67kg:
1 to 2 mins-15mg IVP bolus
>30 mins-50mg IV infusion
>60 mins-35mg IV
3-HOUR Infusion:
≤67kg:
1 to 2 mins- 0.075mg IVP bolus
>60 mins-0.675mg/kg IV infusion
>120 mins-0.25mg/kg IV
≥67kg:
1 to 2 mins-6-10mg IVP bolus
>60 mins-50-54mg IV infusion
>120 mins-20mg IV
100mg IV more than 2 hours
Powder for injection:
2mg (Cathflo activase)
Refer adult dosing
alteplase: it may increase the risk of methemoglobinemia agents
alteplase: it may increase the risk of methemoglobinemia agents
alteplase: it may increase the risk of methemoglobinemia agents
alteplase: it may increase the risk of methemoglobinemia agents
alteplase: it may increase the risk of methemoglobinemia agents
may enhance the risk of angioedema when combined with Alteplase
when both drugs are combined, there may be an increase in the anticoagulant effect
when both drugs are combined, there may be a decrease in the therapeutic effect
when both drugs are combined, there may be a decrease in the therapeutic effect
agents with Antiplatelet Properties
when both the drugs are combined, there might be an increase in the anticoagulant effect
Converting Enzyme Inhibitors- when both drugs are combined, there might be an increase in the anticoagulant effect
when both drugs are combined, there may be an increase in the anticoagulant effect
when both drugs are combined, there may be an increase in the anticoagulant effect
when both drugs are combined, there may be an increase in adverse effects
when both drugs are combined, there may be a decrease in the serum concentration
when both drugs are combined, there may be an increase in adverse effects
when both drugs are combined, there may be a decrease in the therapeutic effect
angiotensin-converting Enzyme (ACE) inhibitors may increase the risk of adverse effects of alteplase
angiotensin-converting Enzyme (ACE) inhibitors may increase the risk of adverse effects of alteplase
angiotensin-converting Enzyme (ACE) inhibitors may increase the risk of adverse effects of alteplase
angiotensin-converting Enzyme (ACE) inhibitors may increase the risk of adverse effects of alteplase
angiotensin-converting Enzyme (ACE) inhibitors may increase the risk of adverse effects of alteplase
may have an increasingly adverse effect when combined with alteplase
may have an increasingly adverse effect when combined with alteplase
may have an increasingly adverse effect when combined with alteplase
may have an increasingly adverse effect when combined with alteplase
may have an increasingly adverse effect when combined with alteplase
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
may increase the anticoagulation when combined with ginkgo biloba
When alteplase is used together with sertraline, the risk or seriousness of bleeding may be enhanced
The potential for bleeding risk or its seriousness may elevate when alteplase is used together with troxerutin
proquazone and alteplase together may make bleeding and hemorrhage more likely
combining alteplase with clonixin may enhance the chance or extent of bleeding and hemorrhage
the risk or extent of bleeding and hemorrhage can be increased when flunixin is combined with alteplase
the risk or extent of bleeding and hemorrhage can be increased when niflumic acid is combined with alteplase
alteplase: it may increase the risk of adverse effects with gestodene
alteplase: it may decrease the therapeutic efficacy of soyabean oil
both forskolin and alteplase enhance anticoagulation
alteplase and ginger together enhance anticoagulation
alteplase: it may decrease the therapeutic efficacy of ceforanide
may decrease the effect of each other through pharmacodynamic antagonism
lisinopril/hydrochlorothiazide
may increase the toxic effect of Angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with alteplase
an increase in severity of hemorrhage and bleeding may be seen when mofebutazone is administered with alteplase
the risk of hemorrhage and bleeding may be increased
the risk of bleeding may be increased
the anticoagulant activity of alteplase may be reduced
the risk of bleeding may be increased
the anticoagulating effect can be increased when aspirin rectal is taken with alteplase
Alteplase is also referred to as tissue plasminogen activator or tPA which acts as a fibrinolytic drug that catalyzes the conversion of plasminogen into the proteolytic enzyme plasmin that in turn degrades fibrin and fibrinogen. After intravenous use, alteplase is mainly metabolised in the liver, with a very short initial half-life of less than 5 minutes and a terminal half-life of 72 minutes. When alteplase is administered at a dose of 2 mg in occluded catheters to retrieve function of the catheters, it will not reach a therapeutically relevant concentration in plasma.
Adverse drug reactions
Frequency defined
>10%
Cardiac arrest
1-10%
Intracranial hemorrhage
Cerebrovascular accidents
Frequently not defined
Sepsis
Hypotension
Bleeding
Arterial embolism
Nausea/Vomiting
Cerebral edema
Thromboembolism
Contraindication/Caution
Do not administer to patients with acute ischemic stroke, pulmonary embolism, concurrent drug therapy issues, or risk of internal bleeding occurs.
Pregnancy/Lactation
Pregnancy consideration: US FDA Category-not assigned
Lactation: The release of the drug in human breast milk is unknown.
Pregnancy category:
Pharmacology
Alteplase is a fibrinolytic agent that targets both fibrin and plasminogen, but due to its high affinity for lysine it selectively acts on fibrin . It also fixes plasminogen through loop formations referred to as kringle domains, and these are composed of three disulphide bridges akin to plasminogen. It is given that the high specificity enables alteplase to act selectively on the clot-bound plasmin-tenase complex in preference to soluble plasminogen, resulting in the perfusion of lower plasma concentrations, which decreases the probability of hemorrhagic transformation.
In patients with acute myocardial infarction, there is a reduction of fibrinogen levels in the range of 3 to 6 hours after alteplase administration. In patients with acute ischemic stroke, an analysis of the results of this trial revealed that alteplase therapy leads to a considerable increase in the proportion of patients with disappearance of the hyperdense artery sign as compared with placebo. However, there are associated complications of alteplase including bleeding complications and thromboembolic complications; cholesterol embolization has also been rarely observed.
Pharmacodynamics
Alteplase transforms plasminogen to plasmin, a proteolytic enzyme that lyses both fibrin and fibrinogen.
Pharmacokinetics
Absorption:
Distribution:
Metabolism:
Alteplase is rapidly cleared from the circulation by the liver.
Metabolites: Degradation products consist of the constituent amino acids of alteplase.
Elimination:
Administration
It is administered intravenous bolus for one minute and infusion remainder for 60 minutes.
Patient information leaflet
Generic Name: alteplase
Pronounced: [ AL-te-plase ]
Why do we use alteplase?
Alteplase is a thrombolytic drug also known as a clot-busting drug. It is used to treat blood clots in the heart and lungs. It is used for the management of acute ischemic stroke through the dissolution of blood clots in the blood vessels. It is administered soon after the patient experiences the signs of a heart attack to enhance their survival rate. It is also given after stroke like signs and for blood clots in the lungs known as pulmonary embolism.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
